DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1093609
Title:
CXCL14 Blockade of CXCL12/CXCR4 Signaling in Prostate Cancer Bone Metastasis
Corporate Author:
Regents of the University of Michigan Ann Arbor United States
Report Date:
2018-12-01
Abstract:
Bone metastasis is a common and unfortunate complication of advanced prostate cancer resulting in significant pain and fractures. The most devastating consequence, however, is that once the cancer has metastasized to bone, the disease is incurable. Up to 90 of men who succumb to prostate cancer have bone metastasis, which demonstrates the strong attraction of prostate cancer to bone. Chemokines are essential in cancer progression and metastasis. The chemokine CXCL14 was identified in a screen for factors that support prostate cancer bone metastasis. In a human prostate cancer tissue microarray, CXCL14 expression was found significantly greater in prostate cancer metastasis to bone compared to metastasis to other organs, suggesting that this chemokine has important effects that are specific to bone. The goal of this proposal is to understand the role of CXCL14 in the homing and progression of prostate cancer to bone.
Descriptive Note:
Technical Report,30 Sep 2015,29 Sep 2018
Pages:
0015
Distribution Statement:
Approved For Public Release;
File Size:
3.61MB
